THE SHORT ANSWER: A common claim in the wellness world is that inflammation drives midsection weight gain in midlife women, and that lowering inflammation is therefore the first move. The published research points mostly the other direction. Visceral fat, the fat stored around the organs, is an endocrine organ. It recruits immune cells and secretes inflammatory signals including IL-6 and TNF-alpha. In a prospective study following women through the menopause transition, increases in intra-abdominal fat correlated with rises in C-reactive protein and falls in adiponectin, and those correlations held after adjusting for the fat sitting under the skin. Inflammation is largely what visceral fat produces. It then feeds back and makes insulin resistance worse, which makes the next round of central storage easier. That's a loop, not a starting point. The distinction changes what's worth measuring and what's worth doing first.
What does the research show about direction?
The most useful data here comes from a prospective cohort that measured the same 69 women before and after the transition, using CT imaging of the abdomen at the L4-L5 level alongside a panel of inflammatory markers and adipokines. Increases in intra-abdominal fat correlated positively with changes in C-reactive protein, serum amyloid A, tissue plasminogen activator antigen, and leptin, and negatively with adiponectin. Critically, the correlations for CRP, tPA, leptin, and adiponectin held after adjusting for change in subcutaneous abdominal fat. The visceral compartment specifically was carrying the inflammatory signal (Lee et al., Journal of Clinical Endocrinology & Metabolism, 2009).
An earlier cross-sectional study using euglycemic clamps compared 45 premenopausal and 44 postmenopausal women. TNF-alpha ran higher after menopause. CRP tracked with total fat in both groups, but only tracked with intra-abdominal fat in the postmenopausal group, and higher CRP went with lower insulin-stimulated glucose disposal in both (Sites et al., Fertility and Sterility, 2002).
The pattern in perimenopausal women is the same. In 230 women aged 44 to 65, those with a BMI at or above 25 had median IL-6 of 4.9 pg/mL versus 2.3, CRP of 3.8 mg/L versus 1.6, and HOMA-IR of 2.6 versus 1.5 compared with women in the normal range (Cybulska et al., Nutrients, 2025).
Worth adding: the assumption that adipose inflammation causes insulin resistance is itself under active debate in the field. A 2024 review in the Journal of Clinical Investigation walked through the history of that hypothesis, from the original TNF-alpha work in the 1990s to the discovery that macrophages rather than fat cells were the cytokine source, and argued the causal story is less settled than a decade of popular summaries have implied (Rosen et al., Journal of Clinical Investigation, 2024).
So is inflammation irrelevant?
No, and that's the part the correction can overshoot.
Inflammation isn't the ignition. It is a real accelerant, and it's a good readout. Once visceral fat is producing IL-6 and TNF-alpha, those signals interfere with insulin signaling, and impaired insulin action makes further central storage easier. That loop is why the trajectory tends to steepen rather than plateau on its own.
There's also emerging work on a gut contribution. A 2024 study found visceral adiposity in postmenopausal women was associated with a pro-inflammatory gut microbiome profile and markers of metabolic endotoxemia, meaning bacterial products crossing the gut barrier and adding to systemic inflammatory tone (Visceral adiposity, gut microbiome and metabolic endotoxemia in postmenopausal women, 2024). That's a plausible additional input. It's association work, not a demonstrated cause, and no human trial has yet shown that manipulating it changes waist measurements. Anyone selling a gut protocol as the fix for midlife midsection change is running ahead of the evidence.
What does an hs-CRP result mean, then?
High-sensitivity C-reactive protein is a useful marker as long as it's read for what it is.
In this population it functions largely as a readout of visceral fat and metabolic strain. A rising hs-CRP alongside a rising fasting insulin and a shifting body composition tells a coherent story. Watching hs-CRP alone and trying to push it down with supplements, while the visceral compartment keeps growing, treats the gauge instead of the engine.
hs-CRP also moves for reasons that have nothing to do with metabolism. Any recent infection, injury, dental work, or hard training block can raise it. A single elevated value in isolation means little. It's a trend marker, and it's read next to other numbers rather than on its own.
The markers that tend to be more informative earlier in this window:
Fasting insulin, drawn with glucose. Insulin rises years before fasting glucose or HbA1c move. A panel reporting glucose alone can read as normal while insulin is doing the work of keeping it there. This is the same argument covered in why "normal" labs and optimal ranges aren't the same thing.
Triglyceride to HDL ratio. Calculated from a standard lipid panel, no additional cost.
SHBG. Sex hormone binding globulin falls as insulin rises, which makes it an indirect and underused signal.
ALT. A rough proxy for liver fat, which tends to move with the visceral compartment.
A body composition measure. Because the thing generating the inflammatory signal is a fat depot, and waist circumference underestimates changes in it. That's covered in why the scale misses what's happening in perimenopause.
What about anti-inflammatory diets and supplements?
Here it's worth separating what's established from what's promising from what's convention.
Established: reducing the visceral compartment reduces the inflammatory signal. A meta-analysis of randomized controlled trials in postmenopausal and older women found resistance training improved body adiposity, metabolic risk, and inflammation compared with controls, and higher-volume protocols produced substantially larger reductions in C-reactive protein than lower-volume ones (Nunes et al., Journal of Sport and Health Science, 2023). Sleep and vasomotor symptom burden matter too. In the SWAN cohort, cumulative exposure to frequent hot flashes across 10 annual visits was associated with a 3.0 cm increase in waist circumference, and the symptom increases preceded the weight changes (Gibson et al., Menopause, 2023).
Plausible, thin human data: omega-3s, curcumin, and berberine have some evidence for moving inflammatory or glucose markers. None have trial data showing a change in visceral fat in perimenopausal women that would justify presenting them as a primary strategy.
Convention without support: IgG food sensitivity panels, zonulin testing, and detox or liver-support protocols marketed for hormone metabolism. The mechanisms sound reasonable. The outcome data isn't there.
Whole-diet quality still matters, and the reason is less exotic than the marketing suggests. A dietary pattern built on protein, fiber, and minimally processed food supports the composition changes that lower the inflammatory signal at its source.
Frequently asked questions
If my hs-CRP is normal, does that mean nothing is happening?
Not necessarily. hs-CRP is one marker with real day-to-day variability, and it can sit in range while fasting insulin and body composition are already moving. It’s read alongside other numbers, not as a single gate.
Does this mean I shouldn't bother with anti-inflammatory eating?
It means the order of operations matters. Diet quality is worth doing. Expecting it to be the lever that shifts central fat accumulation on its own, without a strength stimulus and adequate protein alongside it, sets up a disappointment the research would have predicted.
Why do so many wellness sources say the opposite?
"Inflammation is the root cause" is a clean, memorable story that fits a lot of products. The research is messier, and the messy version is more useful for making decisions.
Is any of this a diagnosis?
No. Nothing in this article diagnoses a condition or tells anyone what their labs mean. Interpretation happens with a provider who has the full clinical picture.
Care in Dartmouth and the SouthCoast
Vitality Dartmouth provides in-person care in Dartmouth, MA, and works with women from New Bedford, Westport, Fairhaven, Fall River, and across the SouthCoast. Our approach to biomarker testing is to look at the panel that shows the mechanism rather than a single marker in isolation. Lab and genomic testing is ordered by our collaborating nurse practitioner or physician. I build the program and coach the training around what those results show.
This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Vitality Dartmouth is an RN-led, physician-supervised clinic. Prescriptions and diagnostic orders are written by our collaborating nurse practitioner or physician. Talk with your own healthcare provider before making changes to your care.